%0 Journal Article
%T Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model
%A Gast¨®n Perman
%A Emiliano Rossi
%A Gabriel D Waisman
%A Cristina Ag¨¹ero
%A Claudio D Gonz¨¢lez
%A Carlos L Pallordet
%A Silvana Figar
%A Fern¨¢n Gonz&#225lez Bernaldo de Quir¨®s
%A JoAnn Canning
%A Enrique R Soriano
%J Cost Effectiveness and Resource Allocation
%D 2011
%I BioMed Central
%R 10.1186/1478-7547-9-4
%X We built a cost-effectiveness model using published evidence of effectiveness of a comprehensive hypertension programme vs. usual care for patients 65 years or older at a community hospital in Buenos Aires, Argentina. We explored incremental cost-effectiveness between groups. The model used a life-time framework adopting a third-party payer's perspective. Incremental cost-effectiveness ratio (ICER) was calculated in International Dollars per life-year gained. We performed a probabilistic sensitivity analysis (PSA) to explore variable uncertainty.The ICER for the base-case of the "Hypertension Programme" versus the "Usual care" approach was 1,124 International Dollars per life-year gained. PSA did not significantly influence results. The programme had a probability of 43% of being dominant (more effective and less costly) and, overall, 95% chance of being cost-effective.Results showed that "Hypertension Programme" had high probabilities of being cost-effective under a wide range of scenarios. This is the first sound cost-effectiveness study to assess a comprehensive hypertension programme versus usual care. This study measures hard outcomes and explores robustness through a probabilistic sensitivity analysis.The comprehensive hypertension programme had high probabilities of being cost-effective versus usual care. This study supports the idea that similar programmes could be the preferred strategy in countries and within health care systems where hypertension treatment for elderly patients is a standard practice.Over the last three decades, clinical research has shown that effective hypertension treatment lowers cardiovascular events and related deaths[1-12]. In spite of this medical benefit there is increasing worldwide concern about the economic burden of hypertension and associated cardiovascular outcomes[13].Mounting evidence shows that multi-intervention programmes are more effective than an isolated pharmacological strategy[14-19]. Special attention is being giv
%U http://www.resource-allocation.com/content/9/1/4